What Happened
A gastroenterologist practicing in Fort Walton Beach, Florida agreed to pay $300,000 to resolve allegations that he violated the Controlled Substances Act (CSA) by unlawfully prescribing opioids and other controlled substances.
The government alleged that from June 15, 2023 through March 7, 2025, he unlawfully prescribed at least 127 controlled-substance prescriptions within Florida — including oxycodone-acetaminophen, hydrocodone-acetaminophen, lorazepam, alprazolam, clonazepam, and tramadol — and did not maintain any patient records for those prescriptions. He voluntarily surrendered his DEA registration on April 22, 2026. In the settlement, announced September 21, 2026, he agreed to pay $300,000, to not reapply for a DEA registration covering Schedule II or IIN controlled substances, to document completion of continuing medical education in prescribing and recordkeeping, and to additional DEA monitoring. This is a civil settlement agreement and is not an admission of liability by the physician.
What Went Wrong
- No patient records behind 127 prescriptions. More than a hundred controlled-substance prescriptions were written over roughly 21 months with no patient records to document the medical basis for any of them.
- Prescriber-only controls, no dispensing-side review. The volume and pattern of prescriptions went unchecked because nothing on the dispensing or pharmacy side flagged a high-volume prescriber writing for multiple controlled-substance classes without corresponding documentation.
- Registration surrender came only after the conduct. The DEA registration was not surrendered until April 2026 — more than a year after the alleged unlawful prescribing had already ended — so it could not have stopped the underlying harm.
- No internal recordkeeping check caught the gap. The absence of any patient records for controlled-substance prescriptions persisted for nearly two years before it became the subject of a government allegation.
How It Could Have Been Prevented
- Maintain a patient record for every controlled-substance encounter, sufficient to make the prescription auditable after the fact.
- Build a pharmacy or dispenser-side second look at high-volume prescribers, rather than relying solely on the prescriber's own records.
- Keep DEA registration status and any conditions on it current, and act on prescribing concerns before — not after — a registration is surrendered.
- Periodically self-audit controlled-substance prescribing volume and recordkeeping completeness against CSA requirements.
Related Guidance
- Diversion prevention checklist — Self-assessment covering prescribing documentation and registration requirements.
- 15 Red Flags of Drug Diversion — Behavioral and transactional indicators, including missing documentation for controlled-substance activity.
- Diversion penalties — How civil settlements and DEA registration actions fit into the broader penalty landscape.
- Diversion case database — Search and filter other verified drug diversion cases.